Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma
This is a Phase III trial to study the effectiveness of nimotuzumab versus cisplatin combined with intensity-modulated radiation therapy (IMRT) in treating patients with stage II-III nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma|Nasopharyngeal Neoplasms|Nasopharyngeal Diseases|Head and Neck Neoplasm
DRUG: Nimotuzumab|DRUG: Cisplatin
Progress-free survival (PFS), Progress-free survival is calculated from the date of randomization to the date of the first progress at any site., 2 years
Overall Survival (OS), The OS was defined as the duration from the date of random assignment to the date of death from any cause or censored at the date of the last follow-up., 2 years|Locoregional Relapse-Free Survival (LRRFS), The LRRFS is evaluated and calculated from the date of random assignment until the day of first locoregional relapse or until the date of the last follow-up visit., 2 years|Distant Metastasis-Free Survival (DMFS), The DMFS is evaluated and calculated from the date of random assignment until the day of first distant metastases or until the date of the last follow-up visit., 2 years|Number of participants with adverse events, up to 2 years
Scheme:

Eligible stage II and III NPC patients will first be stratified by institution, then randomized to 2 arms at 1:1 ratio.

- Arm Cisplatin: cisplatin 40mg/m2/week in concurrent with IMRT

- Arm nimotuzumab: nimotuzumab 200mg/week in concurrent with IMRT